HER2 Testing Characteristics Can Predict Residual Cancer Burden following Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer

Table 5

Multivariate models predicting residual cancer burden following neoadjuvant chemotherapy for HER2+ breast cancer.

Models	Characteristics	OR (95% CL OR)	value
Model 1
	Hormone sensitive (ER or PgR + (10-100%))
	Negative vs. positive	2.85 (1.51-5.38)	0.0012
	HER2 absolute count	1.07 (1.02-1.14)	0.0107
	Pretreatment tumor size	0.83 (0.73-0.95)	0.0060
Model 2
	Hormone sensitive (ER or PgR + (10-100%))
	Negative vs. positive	2.83 (1.48-5.39)	0.0016
	HER2/CEP17 ratio	1.07 (1.03-1.1)	<.0001
	Pretreatment tumor size	0.83 (0.73-0.95)	0.0084
Model 3
	Hormone sensitive (ER or PgR + (10-100%))
	Negative vs. positive	3.19 (1.64-6.2)	0.0006
	IHC stain percentage		<0.0001^a
	3+ 100% vs. 2+	7.59 (2.98-19.35)	<0.0001
	3+ <100% vs. 2+	2.24 (0.74-6.82)	0.1563
	Pretreatment tumor size	0.81 (0.71-0.93)	0.0028

Probabilities modeled are cumulated over the lower ordered RCB values. ^a value is associated with Type 3 analysis of effects.